Xencor Inc

About

Xencor Inc is a leading biotechnology company based in Pasadena, California, specializing in the development of advanced antibody therapeutics for cancer and inflammatory diseases. As a pharmaceutical innovator, Xencor leverages its proprietary XmAb protein engineering platform to create next-generation medicines that expand the therapeutic boundaries of antibody drugs. The company excels in sophisticated Fc domain technologies, including Bispecific Fc Domains for enhanced targeting, Cytotoxic Fc Domains for improved cell killing, Immune Inhibitor Fc Domains for modulating immune responses, and Xtend Fc Domains for extended half-life therapeutics. This comprehensive technology suite enables Xencor to engineer antibodies with superior performance characteristics compared to conventional treatments. Xencor maintains an impressive clinical pipeline with over 20 programs currently in clinical testing across various stages of development. The company has successfully established strategic partnerships with major pharmaceutical companies including Novartis and Amgen, resulting in three XmAb medicines already reaching the market through these collaborations. Operating as a publicly traded company on NASDAQ under the symbol XNCR, Xencor combines cutting-edge protein engineering capabilities with proven commercial success. The company continues advancing its preclinical programs while supporting ongoing clinical trials, positioning itself as a key player in the rapidly evolving cancer immunotherapy and inflammatory disease treatment landscape.